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Technical systems for an accurate and practicable fluid
management of dialysis patients are urgently needed, since
current clinical methods are partially subjective, imprecise,
and time consuming. Such new systems should not only
allow the determination of the target normohydration
weight, but also must be able to detect clinically relevant
changes in fluid volume (B1 l). This study focuses on the
systematic analysis of the detection limit of several candidate
methods for fluid management. In a cohort of 16 new dialysis
patients, several candidate methods were applied in parallel
during each treatment of the initial weight reduction phase:
the measurement of vena cava diameter (VCD), vena cava
collapsibility index (CI), the blood volume drop during an
ultrafiltration (UF) bolus (Drelative blood volume (RBV)), the
rebound after the UF bolus (DRBVþ ), and the extracellular
fluid volume determined with whole body bioimpedance
spectroscopy (BIS). A clinical reference method was used to
manage the fluid status of patients. All methods showed
significant correlations with predialysis weight. The
detection limits Wlim of candidate methods for changes in
fluid status were assessed as Wlim¼ 0.87 kg70.64 kg (BIS),
1.74 kg71.56 kg (VCD), 2.3 kg71.0 kg (DRBV), 7.4 kg7
8.5 kg (CI), 40 kg7108 kg (DRBVþ ). Only BIS shows a
satisfactorily low detection limit Wlim, whereas Wlim was rated
as critical for the VCD and DRBV methods, and as
unacceptable for the CI and DRBVþ methods. Bioimpedance
spectroscopy appears to be the most promising method for a
practical fluid management system in dialysis.
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BACKGROUND
Relevance of fluid status normalization
Increased extracellular volume (ECV) is known to lead to
edema, dyspnoea, and especially hypertension, a consequence
of the increased intravascular volume. Longer-lasting hyper-
tension causes a continuous additional workload to the heart,
which typically leads to left ventricular hypertrophy and
cardiovascular morbidity, including congestive heart failure.
Impaired diastolic or systolic function increases the risk of
onset of hypotension during dialysis, and also of sudden
cardiac death. Furthermore, the presence of edema facilitates
the onset of skin infections, which are frequent especially
in diabetics. Skin infections may give rise to sepsis (which
involves a high mortality risk) and may lead to amputations.
Pulmonary congestion may give rise to bronchitis and
pneumonia, gastrointestinal congestion to malabsorption of
nutrients.
Hypertension is regarded as an important risk factor in the
end stage renal disease (ESRD) population. It is generally
assumed to be caused by salt and volume overload in the
majority of patients. This is supported by the experience
from Tassin, France, where antihypertensive drugs could be
avoided in 98% of patients by using long dialysis treatments,
and a strict fluid removal and dietary salt intake reduction
schedule.1–3 Jaeger and Mehta4 claim that according to several
clinical studies, at least 80% of all hypertension in dialysis
patients is due to chronic volume overload.4 A still existing
fluid overload was found in patients who seemed to show
dialysis-resistant hypertension.5,6 Karzarski5 demonstrated
the relation between fluid overload and hypertension by
showing that hypertensive patients have a significantly
increased ECV compared to normotensive patients and
controls. Again another study7 showed that lowering the
post-dialysis ECV to adequately low values was essential for
achieving normotension. Overhydration was found not only
in hemodialysis patients, but appears to be a similar or even
larger problem in peritoneal dialysis patients.8,9
Despite many studies support the causal relation between
overhydration and hypertension, some studies investigating
the short-term (e.g. intradialytic) response of blood pressure
to fluid volume changes do not detect this correlation.10–12
But this lack of immediate correlation may well be
explained by the large number of clinical experiences
indicating a lag time of several days or weeks between
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a volume change and a succeeding blood pressure change,
as referred by Charra.13
Antihypertensive medications today are very effective in
lowering blood pressures, especially in case of normal volume
state. In a state of overhydration the blood pressure-lowering
effect is somewhat attenuated.14 In many dialysis centers
most patients are on antihypertensives. Nevertheless the
use of such drugs has clear disadvantages compared to
a normalization of blood pressure by elimination of
overhydration: the intravascular volume is still overloaded,
and there may be the risk of a still too high cardiac output or
of insufficient perfusion due to the medication, leaving the
patients on increased risk despite medication. Additionally,
antihypertensive therapy is certainly more expensive than a
reduction of fluid overload.
The mean arterial pressure (MAP) is a predictor for
survival in dialysis patients.1 Avoiding long-term overhydra-
tion and in consequence hypertension therefore is a major
requirement for long-term survival. Achieving a physio-
logically normal fluid status (normohydration) by a practical,
efficient method for fluid status measurement therefore is
a primary goal to avoid critical long-term consequences
for the patient.
Concepts for fluid status assessment
A variety of concepts has been used to quantitatively assess
the fluid status of a dialysis patient. Several comparisons
of such methods have already been published.4,15–18 In the
following, only concepts used in the present study are
described. Other methods for fluid status assessment and
variants of the methods described are existing.
In order to assess the hydration status more quantitatively,
Wizemann and Schilling19 developed a clinical score of
volume state. Typical symptoms for hypovolemia (e.g. thirst,
tiredness, hypotension, and muscle cramps) or hypervolemia
(etc. dyspnoea, edema, and coughing) are observed. Also a
blood pressure increase during ultrafiltration (UF), also
known as ‘paradoxical hypertension,’14 is indicative of
hypervolemia, despite the mechanism is not well understood.
Each symptom, partially weighted according to its severity, is
linked to a number, with negative numbers indicating
hypovolemia, positive numbers indicating hypervolemia. By
summing up numbers related to observed symptoms, a total
score is obtained. Since symptoms are not always specific
for fluid-related problems, they should ideally be scored
only if they appear de novo after a previous symptom-free
state. If such a symptom-free observation phase does not
exist (e.g. in new dialysis patients), all symptoms must be
assumed as fluid related.
This clinical score may be combined with other usually
available information, the pre- and postdialysis blood
pressure and the dose of antihypertensive medication. A
clinical score indicating absence of hypo- and hypervolemic
symptoms, in combination with a blood pressure in the
normal range and absence of antihypertensive medication
may be regarded as a strong indication for a normohydrated
status. This practice of fluid management requires a well-edu-
cated and dedicated staff, and is relatively time consuming and
thereby expensive.
The diameter of the inferior vena cava (VCD) has often
been used with the intent to assess hydration status (e.g.
Ando et al.20, Cheriex et al.21 and Schumacher et al.22). Excess
extracellular fluid increases the intravascular volume, which
in turn typically leads to an increased central venous pressure
and VCD. VCD is typically measured by ultrasonography,
as first reported by Weil and Maurat.23 Since the vena
cava dilates with expiration and collapses with inspiration,
the minimal and maximal diameters VCDmin and VCDmax
are usually measured. The collapsibility index (CI) is the
fractional reduction of VCD during the breathing cycle.
Collapsibility index correlates inversely with central venous
pressure CVP24 and has therefore been regarded another
candidate indicator for fluid status measurement. A large
fluid overload in the vascular system usually leads to a small
collapsibility, and vice versa.
Measurement of relative blood volume (RBV) is another
candidate method for hydration status assessment. Relative
blood volume is the percent change of blood volume from
blood volume at start of hemodialysis and may be measured
easily with existing devices. This method makes use of the
relation between hydration and the intensity of refilling of the
vascular space. The refilling which takes place during and
after a short period of intense UF depends on the fluid
volume in the interstitial space. Higher fluid volumes will
cause an increased interstitial pressure, leading typically to
increased refilling. The drop in RBV during a standardized
UF bolus and the degree of refilling after the bolus should
both depend on the hydration status.
The relation between change in RBV and fluid status has
been mentioned by several authors (e.g. Lopot and Kotyk25
and Steuer et al.26). The drop in RBV from beginning to end
of dialysis tends to be more pronounced in less overhydrated
patients.27 Several authors already used standardized boli for
several purposes. Koomans et al.28 used a relatively long
bolus, removing about UFV¼ 2 l in 1 h, and found a clear
dependence of plasma volume change from tissue hydration
state. Schneditz et al.29 used UF boli with 20 min duration
and an average UF rate UFR of 2.1 l/h for investigating
vascular refilling mechanisms. Wizemann used an UF bolus,
removing 1% of target weight in 15 min, and a follow-up
period of 45 min without UF.30,31 He observed that the less
hydrated the patient is, the more pronounced is the fall in
plasma volume during UF, and the more pronounced is
the rebound after UF. Mitra et al.32 investigated the
kinetics of the blood volume drop with kinetic models,
making extensive use of UF boli (removing 40% of
intradialytic weight gain with UFR¼ 3 l/h) to determine the
patient-specific response. Chamney et al.33 removed the total
UF volume in four boli of decreasing length using an
UFR¼ 4 l/h.
In a whole body bioimpedance measurement the com-
bined electrical impedance of arm, trunk, and leg is measured
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at a specific frequency (mostly 50 kHz). It requires four
electrodes; two attached to the wrist and two to the ankle. Via
the outer electrode pair, a fixed small alternating current I is
applied, and via the inner electrodes a voltage U is measured.
The ratio |Z|¼U/I and the phase shift F between them
depends on the amount and distribution of fluid in the body.
Bioimpedance spectroscopy (BIS) utilizes the variation of the
frequency of the applied current, and thereby allows to
distinguish between intracellular and extracellular fluid
volumes (Figure 1). Since the membranes of the cells in the
current path behave as insulators, the conductivity of tissues
depends much on the frequency. At low frequencies
(B5 kHz), the extracellular space is conducting almost
exclusively. For high frequencies (B1 MHz), the intracellular
pathway is largely accessible additionally since the membrane
shows only a low resistance. At intermediate frequencies the
intracellular space is partially contributing to conductivity.
The frequency variation thereby allows to determine extra-
and intracellular volumes (ECV and ICV) separately (for
details of method see Ackmann and Seitz34, Stroud et al.35,
Ellis et al.36,37, Gudivaka et al.38, Jaffrin et al.39, de Lorenzo
et al.40, Patel et al.41 and van Marken Lichtenbeld et al.42).
Bioimpedance spectroscopy appears to be a straight-
forward approach to measure fluid status since it directly
determines ECV, the expansion of which is assumed to cause
hypertension. Fisch and Spiegel43,44 used BIS to find that
excess fluid in dialysis patients is confined primarily to the
extracellular compartment. Katzarski et al.5 demonstrated
the relation between increased total body water and ECV
to hypertension. They rated BIS as a highly reproducible
and technically simple method, which is useful for dry
weight assessment in dialysis patients. Also Oe et al.45
conclude from BIS measurements that fluid removal reduces
ECV and that measured volumes seem appropriate to assess
hydration status in hemodialysis patients. However, a
specific concept on how to derive the normohydration
weight (dry weight) from BIS measurements has not yet
been described.
Goal of the study
The goal of this study is to evaluate candidate methods for
the assessment of fluid status in hemodialysis patients. Focus
of the study is on determination of the detection limit
of methods only (see Materials and Methods section
and Figure 2 for a precise definition of detection limit). A
sufficiently low detection limit is a basic requirement for a
clinically useful method for fluid status assessment. It is not
sufficient that a method just shows a correlation to fluid
status changes. It is a precondition that the many undesired
effects influencing measurements with each candidate method
are small enough that clinically relevant changes in fluid status
can still be derived from the measurement with sufficient
accuracy. In this way, this study aims at a precise analysis of a
specific performance characteristic (the detection limit) of
candidate methods for the assessment of fluid status.
The basic concept of this study is to move new dialysis
patients from their initially overhydrated status to a
normohydrated status, using a clinical assessment of hydra-
tion status. In parallel, the candidate methods (vena cava-,
blood volume- and bioimpedance-based concepts) are
applied to determine their detection limit for fluid status
changes. These candidate methods are not used to determine
the normohydration status. In this setting, the clinical
assessment is the reference method, the candidate methods
are the test methods. Using all methods in parallel in each
dialysis treatment of this study allows a direct comparison of
performances.
RESULTS
In the following ‘Pn’ will be used as an abbreviation for
‘patient no. n’.
Weight reduction scheme
Depending on the weight reduction required to achieve
the normohydrated weight according to clinical assessment,
it took between 1 and about 4 weeks, in one case almost
9 weeks (P16), to move a patient into a normohydrated status
(Figure 3). On average 10 treatments, or 3.3 weeks, were
required in this group of patients. The postdialysis weights
were always changed in moderate steps (typically 0.5–1.5 kg)
to allow the patient to adapt to the reduced fluid volume.
Nevertheless, in some cases a temporary increase in
postdialysis weight was required to allow the patient to
better adapt to the restricted fluid volume.
The predialysis weight reductions between the treatments
with the maximum and minimum predialysis weight are
Low frequency: extracellular current
paths dominate
High frequency: intracellular current 
paths additionally contribute
Intermediate frequency: intracellular 
current paths partially contribute
~ 5kHz
~ 1 MHz
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Figure 1 | Principle of bioimpedance spectroscopy for differen-
tiation between intra- and extracellular fluid volumes.
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Figure 2 | Principle of determination of the detection limit Wlim
from the s.d. ry of single measurements and the slope sy of the
linear regression of a measured set of clinical data y(Wpre) (see
text for details).
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shown in Table 1. Also total weight reductions (between start
of first and end of last treatment) are listed, which were
between 2.2 kg (P8) and 13.8 kg (P16), on average 7.0 kg. This
total weight reduction is not necessarily identical to the initial
overhydration of the patient, as will be discussed later.
Clinical assessment of normohydration
Figure 4 shows the clinical score (CS) and the equivalent dose
of antihypertensive medication equivalent dose (ED), as well
as MAP and heart rate HR for two selected patients (P2 and
P5) with relatively large weight changes during the study.
Measurements are generally plotted as function of predialysis
weight Wpre, because they refer to the condition of the
patient directly previous to or at the beginning of the dialysis
treatment.
Clinical score frequently decreased (almost steadily) with
decreasing predialysis weight Wpre, starting from a level
indicating significant overhydration, and finally reached 0
(P2 and P5). Equivalent dose typically followed roughly the
course of CS. This means of course that a reduction of
overhydration-related symptoms, indicated by a decrease in
CS, usually caused the clinician to reduce antihypertensive
medication in this study. Whereas in P2 MAP showed
a pronounced reduction with decreasing Wpre, P5 showed
only a small reduction. HR remained largely unaffected by
fluid reduction in these two patients.
For a more systematic analysis, changes in CS, ED, and
MAP during the study in all 16 patients are summarized in
Figure 5. HR remained unaffected by weight reduction in
almost all patients; there was obviously no detectable
correlation of HR to fluid status changes.
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Figure 3 | Postdialysis weights Wpost during the phase of clinical
dry weight adjustment as function of time since first dialysis for
all 16 patients. Patient numbers are shown for comparisons with the
following graphs. Each data point represents a dialysis treatment
involving the complete set of measurements.
Table 1 | Patient characteristics, maximum change in predialysis weight DWpre and total weight reductions DWmax for each
patient (details see text)
Patient no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Age (years) 55 72 81 84 50 68 65 73 44 42 70 67 67 24 64 45
Gender M M F M M M M F F M M M F M F M
Diabetes Y Y Y N Y N N Y Y N Y N N N Y Y
DWpre (kg) 0.9 9.0 9.6 2.5 9.6 5.2 3.3 0.9 6.2 3.0 5.4 5.0 1.1 3.7 9.4 10.8
DWmax (kg) 3.5 10.2 10.5 3.6 11.7 7.4 4 2.2 8.8 3.5 7.7 6.2 2.5 3.9 12.3 13.8
F, female; M, male; N, no; Y, yes.
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Figure 4 | Clinical score CS and equivalent dose ED (upper
panels), mean arterial pressure (MAP) and heart rate (HR) (lower
panels) as function of predialysis weight Wpre for two selected
patients. ED is an estimated equivalent for the effect of the
antihypertensive medication of the patient (details see text).
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Figure 5 | Maximum and minimum clinical scores (CS) (left panel),
initial and final equivalent doses (ED) of antihypertensive
medication (mid panel) and initial and final mean arterial
pressures (MAP) (right panel) for each of 16 patients. For patients
10, 13, and 14 initial and final CS is identical. For patients 1, 14, and 16
initial and final ED is identical.
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The minimum and maximum CS for each patient during
the study period is shown in Figure 5a. The maximum CS
(which is identical to the initial CS except for P16) ranged
from 0–8, with an average of 3.25. The minimum CS, which is
identical to the final CS, was always 0 (since this is a
requirement for considering a patient as normohydrated),
except for P8, who refused a further weight reduction despite
obvious signs of overhydration. Negative values of CS
(indicative of underhydration) were never observed; under-
hydration could be avoided since patients were very well
surveyed in this study and reduction of postdialysis weight
occurred in small steps, especially at the end of the study
period. In Figure 5b the maximum (initial) and minimum
(final) ED during the study period is shown for each patient.
One patient (P8) was noncompliant with unclear medication;
data on ED are therefore not shown for this patient. The
initial ED ranged between 0 and 8.75 U, with an average of
2.9 U. The final doses ranged between 0 and 2 U, with an
average of 0.4 U. The initial ED always was identical to the
maximum ED, the final ED identical to the minimum ED.
For P1 and P14 who showed low weight reductions DWpre, a
low level of antihypertensive medication was kept unchanged.
For all other patients ED was lowered by between 80 and
100%. P16 did not receive antihypertensive medication
during the study (ED¼ 0 U). The average reduction in anti-
hypertensive medication achieved in this study (omitting P8
and P16), as measured by ED, was 82%.
The reductions DCS and DED between start end of the
study period might be expected higher in patients showing a
large weight reductions DWpreX9 kg (P2, P3, P5, P15, and
P16). In fact, only quite weak correlations of DCS and
DED with DWpre were observed; a possible reason will be
discussed below.
Initial and final MAPs (Figure 5c) refer to MAPs at the
beginning of the first and last treatment during the study
period. These MAP data were derived from the linear
regression line of the measured MAP data; this approach was
used because single MAP measurements may deviate largely
from the regression line (compare Figure 4c). Normal or only
slightly supranormal MAPs were achieved at the end of the
study period for most patients. In patients with high initial
MAP (MAPinitX110 mmHg), a considerable reduction of
MAP was achieved. In these initially hypertensive patients
(partially despite considerable antihypertensive medication),
MAP could be significantly decreased by weight reduction,
despite a parallel reduction in antihypertensive medication
(Figure 5b). Of 10 patients with MAPinitX95 mmHg, eight
showed a significant reduction in MAP with decreasing
weight despite reduction in antihypertensive medication.
The remaining two patients had constant ED; one showed
a pronounced MAP reduction (P14), the other (P16) had
an almost constant MAP. This result demonstrates clearly
the benefits of eliminating overhydration in order to avoid
hypertension in most patients.
For two patients with about normal MAPinit, MAP slightly
increased (P1 and P4). P7 showed a very low MAPinit, which
increased largely towards the normal range during the study
despite reduction in ED.
Assessment of candidate methods: general remarks
Measurements with the candidate methods for fluid status
assessment and the analysis of their detection limits are
presented in Figures 6–9. Exemplary of all measurements
performed, Figure 6 shows measurement results with all
candidate methods for 2 patients (P2 and P5). Data points
are connected in sequence of the dialysis treatments
performed (starting on the right at large weights). These
examples, which will be discussed in detail below, provide
already a first impression on the detection limits of methods
by visual inspection (as defined in Materials and Methods,
the detection limit is related to the scatter around the
regression line, and the slope of this line). It is obvious that,
for example ECV, measured by bioimpedance, is a more
appropriate measure of fluid status changes than DRBVþ
measured by blood volume monitoring.
For a more systematic analysis of methods, linear
regressions of measurements (shown as dotted lines in
Figure 6) were performed for all patients. Linear functions
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Figure 6 | Responses to weight reduction in two patients,
measured by ultrasonography (vena cava diameter (VCD),
collapsibility index (CI), blood volume monitoring (blood volume
drop DRBV and rebound DRBVþ ) and bioimpedance spectro-
scopy (intra- and extracellular volumes (ICV and ECV)), as
function of predialysis weight Wpre.
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fitted best for all methods; there was no reason for using
higher-order functions. Slopes sy, s.d. around the regression
line sy, and s.e. of slope ss,y were determined as described in
Materials and Methods. Slopes and s.e. of slope are shown in
Figure 7 for all candidate methods. Data are plotted as
function of the change in predialytic weight DWpre achieved
during the study (listed for each patient in Table 1). Standard
errors of slope ss,y are larger for patients with a smaller
DWpre, because of the smaller range of weight variation and
the smaller number of measurements involved. Data for 3
patients (P1, P8, and P13) with very low predialysis weight
changes DWpreo2 kg during the study period were omitted
since a reliable slope calculation was not possible. For
the remaining 13 patients, average slopes sy_av, average s.e. of
slope ss,y_av and fit parameters ss,y_av/sy_av were calculated for
each measured variable y.
VCD and collapsibility
In P2 and P5, pronounced drops from maximum to
minimum VCD of 59 and 67% were observed (Figure 6a
and b). Vena cava diameter dropped with decreasing Wpre in
all patients, as indicated by significantly positive slopes sVCD
for all patients (Figure 7a). VCD responded strongly to fluid
reduction, but also showed considerable scatter around the
regression line (see e.g. P2 in Figure 6a), despite measure-
ments were performed by a well-trained person. sVCD varied
between 0.24 and 2.5 mm/kg; the average reduction in VCD
was 1.1 mm/kg of weight reduction (sVCD_av¼ 1.1 mm/kg).
P16 showed the lowest sVCD. The average s.e. of slope
ss,VCD_av was 0.29 mm/kg, the fit parameter ss,VCD_av/sVCD_av
was 26%.
P5 showed the usually expected increase of CI with weight
reduction (from 27 to 79%; Figure 6b). Such an increase is
indicated by a significant negative slope sCI (Figure 7b). No
patient showed a positive sCI with significance. However,
only two patients (P5, P15 with DWpreB9.5 kg) showed
a significant negative sCI (the significance for some patients
with low DWpre seems questionable). In at least six of 13
patients, no clear variation of CI with Wpre was observed, as
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Figure 7 | Analysis of candidate methods for fluid status assess-
ment: slopes s and s.e. of slope rs (indicated by error bars) are
plotted as function of DWpre, the change in predialytic weight
achieved during the study. Each of the six plots refers to one of six
measured variables (VCD, CI, DRBV, DRBVþ , ECV, ICV) for 13
patients (all patients with DWpre42 kg).
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Figure 9 | Final ranking of the five candidate methods according
to their detection limit Wlim for changes in fluid status: the box
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indicated by sCI close to 0%/kg. For example, in P2 CI varied
between 20 and 48% without a clear trend (Figure 6a),
despite VCD showed a strong dependency on Wpre. sCI varied
between –8.9 and þ 1.0% per kg; the average increase in CI
was only 3.1% per kg weight reduction (sCI_av¼3.1 %/kg).
Generally, the scatter of CI around the trend lines was even
higher than for VCD: the average s.e. of slope ss,CI_av was
2.3%/kg, the fit parameter ss,CI_av/sCI_av was 74%.
In summary, VCD increased with Wpre in all patients and
showed a moderate correlation with Wpre. Collapsibility index,
in contrast, showed much less correlation with Wpre, and even
did not show a significant change with Wpre in many patients.
Blood volume response to UF boli
In P2, a doubling of the blood volume drop DRBV from
2.7 to 5.4% during weight reduction period was observed
(Figure 6c). In parallel, the rebound DRBVþ reduced from
DRBVþ ¼ 5.8 to 2.5%. Results for P5 were very similar
(Figure 6d).
As indicated by the positive slopes sRBV (Figure 7c), the
trend to larger drops |DRBV| with decreasing weight Wpre
could be recognized in all patients. sRBV was in the range of
0.08–0.34% per kg weight reduction, on average 0.23% pre kg
(sRBV_av¼ 0.23%/kg), with P16 showing the smallest sRBV.
Many patients showed a decreasing refilling DRBVþ
(indicated by a positive sRBVþ in Figure 7d) with decreasing
weight Wpre, but there are also patients in which no change in
refilling was observed (sRBVþ close to 0% per kg). sRBVþ
ranged between 0.05 and þ 0.79% per kg weight reduction,
on average þ 0.22% per kg (sRBVþ _av¼ 0.22% per kg). There
was considerable scatter of measurements around the
regression lines, which prevented from detecting clear trends
in patients with small DWpre. The scatter obviously was
higher for the rebound (DRBVþ ) than for the drop during
UF (DRBV) measurements. The average s.e. of slope were
ss,RBV_av¼ 0.12% per kg, ss,RBVþ _av¼ 0.23% per kg. The
fit parameters were ss,RBV_av/sRBV_av¼ 52%, ss,RBVþ _av/
sRBVþ _av¼ 105%.
Assuming no refilling and absolute blood volumes of 4–6 l,
a UF bolus of 0.25 l would reduce RBV by DRBV¼
4.2–6.25%. The average drop observed at the end of this study
was DRBV¼ 5.171.2%, indicating that at the beginning of
the last treatment refilling during the UF bolus was already
relatively low.
In summary, the drop in RBV during an UF bolus and the
RBV rebound after the bolus both showed a dependency on
the degree of overhydration in most patients. The average
slopes for the drop during UF and for the rebound were
almost identical, but the s.e. of slope, indicating the
correlation between change in RBV and change in Wpre,
was much smaller (indicating a better correlation) for the
drop during UF.
Bioimpedance spectroscopy
The predialysis bioimpedance measurement could not be
successfully performed in 16 of 161 treatments due to
technical problems. Sometimes insufficient electrode contact
to skin was suspected; also electrical interference or problems
with cables connecting device and electrodes seemed relevant.
Improvements concerning these technical problems are
desirable. Aside from these problems, the bioimpedance
measurement could be performed easily and reproducibly.
A clear reduction in ECV with decreasing predialysis
weight Wpre was observed in P2 and P5 (Figure 6e and f).
Such a pronounced reduction was observed in all patients
(Figure 7e), as indicated by significant positive slopes sECV for
all patients. Observed trends were clearly linear. sECV varied
between 0.164 and 1.29 l/kg, with an average of
sECV_av¼ 0.614 l/kg. Consistently positive slopes support the
idea that overhydration mainly leads to an expanded ECV. A
sECV close to 1 l/kg would mean that nearly all weight
reduction is derived from ECV, and weight reduction in this
situation is identical to a sole reduction in overhydration.
This condition seems to be approximately valid for P2
(Figure 6e) with a sECV¼ 0.94 l/kg. Most patients showed
smaller values of sECV, but one patient also exceeded
sECV¼ 1 l/kg (P14). Possible explanations will be discussed
below. The average s.e. of slope ss,ECV_av was 0.096 l/kg. The
fit parameter ss,ECV_av/sECV_av was 15.6%, reflecting the
relatively low scatter of measured data around the regression
lines for ECV.
Only ECV, not ICV, is regarded as a potential indicator for
fluid status. Nevertheless, ICV is included in this analysis for
reasons that will become clear in the discussion. ICV trends
differed between patients (Figure 6e and f and 7f) and were
generally smaller than for ECV. Several patients showed a
moderate reduction of ICV with decreasing Wpre, whereas
ICV remained largely unaffected in other patients and even
increased in one patient (Figure 7f). sICV ranged from 0.37
to þ 1.01 l/kg, with an average of sICV_av¼ 0.136 l/kg. Since
ICV is related to the body cell mass, positive sICV could be
interpreted as a loss in body cell mass during the study
period. The average s.e. of slope ss,ICV_av was 0.145 l/kg, the
fit parameter ss,ICV_av/sICV_av was 107%.
Absolute values of ECV may be considerably larger than
ICV (e.g. P2 at initial measurement), but may also be much
lower than ICV in another patient (P16; not shown).
In summary, the drop in ECV correlated very well with the
reduction in Wpre. Typically, a large part of weight reduction
seemed to be derived from ECV. However, there were other
important effects contributing to the observed weight
reduction, as indicated by changes in ICV, which will be
discussed below.
Comparative analysis of detection limits
In order to compare sensitivities of candidate methods for
changes in fluid status, the detection limit Wlim was
determined for each patient and for each candidate indicator
(VCD, CI, DRBV, DRBVþ, ECV).
Figure 8 shows the detection limits Wlim for some selected
patients. P10 is the patient who showed the lowest Wlim (on
average of all methods), P16 showed the highest. It is evident
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that the CI and DRBVþ methods show a very high Wlim. In
P6 the VCD method performed better than the ECV method,
in P9 and P16 much worse. For 11 of 13 patients the
detection limit was best (lowest) for the ECV method, and
the remaining two patients (P4 and P6) showed lowest Wlim
for the VCD method. Comparing the ECV method in
different patients, the worst (highest) Wlim was found in
P6 (Wlim¼ 2.8 l) because slope sECV was very low; in 12
of 13 patients Wlim was o1.3 l, in 10 of 13 patients Wlim
was o0.9 l for ECV.
Figure 9 summarizes the results of the study: the box plot
indicates the variation ranges and the median of detection
limits in 13 patients for each candidate method. The average
Wlim_av and the s.d. Wlim_sdv of the detection limits for each
method is also listed. The CI and DRBVþ methods show the
highest (worst) detection limits of all methods. The DRBV-
method provides a detection limit of Wlim_av¼ 2.371.0 l; the
VCD method shows a slightly lower Wlim_av¼ 1.74 l, but has
a much worse s.d. Wlim_sdev¼ 1.56 l. The lowest (best)
detection limit is provided by the ECV method
(Wlim_av¼ 0.8770.64 l), showing an average and s.d. about
a factor of 2 better as compared to the VCD method. The fit
parameters ss,y/sy (listed in Results for each candidate
method separately) lead to the same ranking of methods
and thereby further confirm the result of the analysis of
detection limits.
DISCUSSION
Evaluation of methods
The study described intends to make a contribution to the
solution of the dry weight problem by identifying methods
which are sensitive enough to detect clinically relevant
changes in fluid status. The authors believe that a useful
method should have a detection limit of about 1 l (or 1 kg),
meaning that changes in overhydration of 1 l are detected in
the majority of cases. There are two methods (blood volume
rebound after an UF bolus DRBVþ and CI) which show
clearly unacceptable detection limits. These methods are
definitely not appropriate as candidate methods for mon-
itoring fluid status. Two other methods (VCD and the blood
volume drop during an UF bolus DRBV) show critical,
probably still too high detection limits for a useful clinical
application. The results of this study demonstrate that only
the measurement of extracellular fluid volume ECV has a
sufficiently low detection limit. This method therefore
appears to be the most promising candidate method for
a practical fluid management in dialysis.
The clinical assessment of fluid status by a clinical score
(used as a reference method in this study) obviously does not
achieve the required detection limit of 1 l. It is interesting to
notice (Figure 4) that the clinical score CS may reach 0,
indicating the absence of symptoms of overhydration, at
considerably higher weights than the final predialysis weight,
at which the patient will be regarded as normohydrated after
the treatment (especially pronounced in P5, Figure 4b).
Assuming that the final postdialysis weight is close to the
normohydration weight, the data allow the conclusion that
overhydration-related symptoms require typically at least 2 l
of overhydration remaining after dialysis; in some patients
(P2, P3, and P5) even 3–6 l of overhydration seem to be
required until symptoms (indicated by CS40) develop. In
conclusion, CS is hardly sensitive to small to moderate levels
of overhydration, whereas large overhydrations are clearly
indicated by CS.
Mean arterial pressure is also frequently used within a
clinical assessment of fluid status. The dependency of MAP
from Wpre is obviously highly variable in this group of pati-
ents and MAP is influenced not only by overhydration. This
result is not surprising since cardiovascular dysfunctions,
antihypertensive medication and short-term compensatory
mechanisms in response to fluid removal may hide an
expected drop in MAP with fluid reduction.
The correlation between weight and overhydration
The physiological variables measured by the candidate
methods were plotted as function of predialysis weight Wpre
in Figure 6. It is important to realize that the change in
weight is not necessarily caused by a change in overhydration
alone. Usually it takes some weeks to get the patients into a
normohydrated state, because a faster reduction of weight
would induce adverse symptoms. Within this time, the lean
tissue mass and the fat mass of the patient also may
considerably change. These changes may be even more
pronounced in the phase of starting dialysis therapy which
was observed during this study, where major changes in
appetite, metabolism, physical activity are probable. There-
fore, the change in overhydration cannot easily be derived
from the observed weight changes of a patient.
This is also probably a reason for the observed variability
in patient responses to weight change: the same weight
change can mean different changes in overhydration in
different patients. This would give rise, for example, to the
observed variability in slopes sECV or sVCD.
The relevance of these considerations can be demonstrated
best with the example of patient 16 (P16), who was
exceptional in almost any type of measurement: P16 showed
the largest predialysis weight reduction (10.8 kg) and thereby
would be expected to show signs of large overhydration
initially and a considerable reduction in indicators of
overhydration during the study. However, initial clinical
score CS was low (Figure 5), and showed no clear trend to
decrease (data not shown); MAP was only moderately
increased, and did not reduce with weight; antihypertensive
medication was not used; the reductions per kg weight loss in
VCD and DRBV were the lowest of all patients (only ECV
decreased moderately). Despite massive weight reduction, all
indicators of overhydration demonstrated consistently only
moderate overhydration, which hardly decreased during 9
weeks of weight reduction. It is highly probable that P16 lost
mainly lean tissue and/or fat, and thereby hardly reduced
overhydration. The clear reduction in ICV of around 3.2 l in
P16 indicates a loss of B5 kg of body cell mass. The ECV
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which surrounded this cell mass thereby will end up as
additional excessive fluid. This explains why the removal of
about 6 l of ECV did hardly cause a reduction in over-
hydration. After end of the study, the patient revealed that he
performed a massive weight reduction diet on his own
decision during the study period.
In contrast to P16, the weight reduction in P2 seems to be
caused almost completely by overhydration reduction (each
kg weight loss reduces ECV by 0.94 l). This patient shows a
high reduction in clinical score (DCS¼ 5) and also one of the
highest reductions in the equivalent dose of antihypertensive
medication (DED¼ 4) at a predialysis weight reduction of
9 kg. In P10, both slopes are close to 0 (sECV¼ 0.16 l/kg,
sICV¼0.2 l/kg) and DCS¼ 0, indicating that a considerable
fraction of the predialysis weight change is probably due to
loss of fat (which should hardly affect water volumes). P14
shows a sECV significantly above 1 l/kg (sECV¼ 1.29 l/kg)
and a negative sICV (sICV¼0.37 l/kg), probably indicating
that the patient gains lean tissue mass during the weight
reduction period.
Generally, the observed weight change during the study
period is the sum of changes in overhydration, lean body
mass, and fat mass. The changes in ECV and ICV (or the
slopes sECV and sICV) give an indication on the changes that
occur in each patient. Bioimpedance spectroscopy can
obviously provide an at least qualitative insight into the
changes in body composition. It also becomes obvious that
the measurement only of ECV is insufficient for determina-
tion of overhydration: ICV, which is related to lean tissue
mass, is certainly required to determine which part of the
measured ECV is excess fluid and which part is tissue-related
extracellular fluid. Work to develop a quantitative method for
body composition analysis (including overhydration measure-
ment) is in progress. A future bioimpedance spectroscopy
system then might be able to directly display the weight at
which the patient is normohydrated and his amount
of overhydration.
Further requirements for a practical fluid management
A clinically useful method for fluid status assessment would
not only have to demonstrate a sufficiently low detection
limit. Also an algorithm would be required to determine
a target value for the measured variable (e.g. VCD, DRBV,
and ECV) which corresponds to the individual normohydra-
tion level. Furthermore, a useful method must be practicable
in daily use, and should not involve high additional costs.
For the VCD method, the determination of a target VCD
appears to be critical: in a group of 42 healthy subjects no
significant correlation of VCD with body weight, age or
gender was found by Ando et al.20 VCDmin was 5.775.4 mm,
VCDmax was 16.773.2 mm, CI was 0.6870.29. Therefore, it
remains unclear how an individual target value derived from
VCD can be determined. Kusaba et al.46 measured VCD in
the expiratory phase and suggested that VCD¼ 11.07
4.3 mm postdialysis could be interpreted as being close to
dry weight. However, the range given here seems much too
high for defining a useful target diameter. In dialysis patients,
VCD may be expected to be influenced by the common
cardiovascular problems as pulmonary hypertension, chronic
obstructive lung disease, severe arrhythmia, myocardial
infarction, valve dysfunctions, etc.20 In such patients VCD
may be largely increased even without overhydration, making
a determination of fluid status from VCD impossible. Vena
cava diameter measurements involve an expensive ultrasound
unit and require an experienced user. Additionally the
measurements are somewhat user dependent and also may
be affected by the compliance of the patient. Practicability
and costs are therefore questionable for a routine application.
For the DRBV method, there is currently no concept for
determining a target DRBV corresponding to normohydra-
tion. Nevertheless, it might be possible to develop such a
concept. A model describing refilling as function of hydration
status would be required. Increasing the UF bolus volume
might also improve the detection limit, but increases the risk
for inducing hypotension, and also might interfere too much
with the UF regime. The method has a good practicability,
since the generation of the UF bolus and the measurement
with a blood volume monitor can be fully automated.
A blood volume monitor and a specific disposable for each
measurement would be required. Costs are acceptable
(similar to bioimpedance); there would be no additional
costs of equipment if blood volume monitors are already
used for UF control.
For the bioimpedance method, first approaches to
determine a target ECV which corresponds to normohydration
have already been developed.47 Further developments in this
field are expected to allow to derive the individual body
composition of a patient (lean body mass, fat mass, and
overhydration). The target ECV then would be derived from
the individual body composition of the patient, determined
from bioimpedance measurement and anthropometric infor-
mation. A bioimpedance measurement is practicable, because
it takes only 10–15 min (including preparation time) once to
twice monthly and can be easily managed by trained staff. Also
costs are acceptable, since a device might be used for many
patients and costs of electrodes are B1$ per measurement.
Bioimpedance also appears to be destined for fluid status
assessment since it involves the direct measurement of the
fluid spaces that make up the hydration status of the body.
In summary, bioimpedance spectroscopy appears to be the
most promising method for a practical fluid management
system in dialysis. The blood volume method requires further
development to see whether a sufficient performance can be
achieved.
MATERIALS AND METHODS
Study design
Sixteen consecutive patients starting dialysis therapy at the Georg
Haas-Dialysezentrum, Giessen, Germany, were recruited for this
study within a time interval of 13 months. No further criteria for
patient selection were used. Age range was from 24 to 84 years; five
patients were female, 11 male; nine were diabetics. Patients were
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monitored during each treatment during the study period. A total of
161 treatments were performed. The target weight of dialysis
patients was reduced in steps of typically 0.5–1.5 l from one session
to the next. Reduction of dry weight was terminated once a patient
was regarded as ‘dry’ (normohydrated) after dialysis, according
to clinical criteria (to be described below). For the purpose of
this study, it is not important whether the patients are really
normohydrated at end of their study period; it is more relevant
to achieve large changes in fluid status, in order to observe the
response of the candidate methods. All measurements with these
methods were performed predialysis. Postdialysis measurements
were assumed to be less conclusive due to many dialysis-induced
disequilibrium conditions in the body; also they appear less
practicable and seem to present no advantage.
Patients were treated with Fresenius 4008 dialysis machines,
equipped with a blood temperature monitor and a blood volume
monitor. A supine position of the patients during the treatments was
preferred, but was not possible for several of them. Patients were
asked not to take up food during treatments; drinking was limited to
B100 ml. Erythropoietin was administered according to the
individual needs of the patients. The thermal energy balance control
feature of the blood temperature monitor was used in order to
provide reproducible thermal conditions during the treatments
(otherwise uncontrolled changes in heat balance may affect blood
pressure measurements).
Clinical score, blood pressure, heart rate
A score similar to the one published by Wizemann and Schilling, but
with some modifications for a more detailed listing of symptoms
was used (see Table 2). The score was measured for each single
dialysis treatment by evaluating symptoms during dialysis, and
filling in a questionnaire about symptoms observed by the patient
himself since the last treatment. All symptoms in this study were
listed by the same person, which eliminated observer interference.
Blood pressure and heart rate measurements were obtained
predialysis (after connection of the extracorporeal circuit to the
patient, before start of UF). Both were measured with the Fresenius
blood pressure monitor. Mean arterial pressure was calculated from
measured systolic and diastolic blood pressures BPsys and BPdia
according to the usual equation:
MAP ¼ ð2  BPdia þ BPsysÞ
3
: ð1Þ
In this study, target weight was lowered until the score reached 0. If
the patient then was still hypertensive, a further reduction of target
weight was performed. Finally, the reduction of target weight was
stopped when the physician either regarded the patient as
normohydrated or when a further reduction seemed not recom-
mendable due to cardiovascular or other problems.
Equivalent dose of antihypertensive medication
All patients except one (patient 16) were on antihypertensive
medication when entering the study. a-blockers, b-blockers, ACE
inhibitors, vasodilators, and Ca antagonists were used in the study
population. Five patients were on monotherapy, nine patients
received combinations of up to five different medications. For the
purpose of this study it seemed useful to define an equivalent dose
ED, which provides a rough measure for the total dose of
antihypertensives. Equivalent dose allows to follow changes in the
individual medication and to compare medication between patients
quantitatively. For any of the ingredients of the drugs used, Table 3
shows which amount was assumed to correlate to 1 ED unit¼ 1 U.
This approach certainly has its limitations, since a substance may
have largely different effects in different subjects or even in the same
subject in different physiological conditions (e.g. degree of over-
hydration!). Nevertheless, for the purpose of monitoring and
comparing dose changes the approach was regarded as justified.
Before each dialysis, the dose ED used during the previous days
including the treatment day was listed.
Vena cava measurements
The VCD was measured approximately 30 min before start of
dialysis with a Siemens Sonoline SL-1 device located in a separate
room. Diameter measurements were taken directly distal of the
inflow of the hepatic veins, at maximum inspiration, maximum
Table 2 | Clinical score of volume state
Clinical score of volume state
Symptoms of hypovolemia
Thirst directly after HD 1
Sympt. hypotension, position change 1
Sympt. hypotension, requiring saline infusion 2
Muscle cramps, moderate (calf) 2
Muscle cramps, severe (calf) 3
Limpness/tiredness between dialyses 3
Dizziness between dialyses 4
Sympt. hypotension, vomiting 6
Indication of euvolemia
Absence of symptoms given in this table 0
Symptoms of hypervolemia
Blood pressure increase during UF +2
Pretibial edema, weak +2
Chronic coughing (new) +2
Dyspnoea at rest, recumbent +2
Pretibial edema, severe +3
Dyspnoea at rest, one cushion +3
Dyspnoea at rest, two cushions +4
Dyspnoea at rest, sitting +6
HD: hemodialysis; UF: ultrafiltration.
Table 3 | Table of antihypertensive medications used in this study, and amounts of medications that correspond to one
equivalent dose unit (1 ED unit)
Ingredient 1 ED unit equivalent (mg) Ingredient 1 ED unit equivalent (mg) Ingredient 1 ED unit equivalent (mg)
Nifedipine 10 Doxazosin 4 Amlodipine 5
Nitrendipine 20 Carvedilol 25 Enalapril+HTC 1 tbl.=2 U
Metoprolol 50 Diltiazem 90 Eprosartan 300
Clonidine 0.075 Felodipine 5 Isradipine 5
Ramipril 2.5 Dihydralazine sulfate 25 Enalapril 5
ED, equivalent dose; 1 ED unit=1 U.
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expiration, and in a neutral breathing position. Readings were taken
during a short phase of stopped breathing in the respective
situation. Collapsibility index was calculated according to
CI ¼ ðVCDmax  VCDminÞ
VCDmax
: ð2Þ
For further analysis the diameter at neutral position (VCD) and the
CI were used. These measurements were not referenced to body
surface area, since this is not relevant for the analysis of detection
limits in single patients. Since all measurements were done by the
same person, the well-known interobserver variability of this
method was excluded.
Generation of UF boli and measurement of blood
volume changes
A standardized UF bolus was used with a relatively small bolus
volume of UFV¼ 0.25 l. This UFV is large enough to generate
precisely measurable RBV changes, but small enough to avoid
induction of cardiovascular instability.
During the first minutes of the treatment the UF rate (UFR) was
kept at 0 l/h until stabilization of RBV was achieved. Then the UF
bolus was started with an UFR¼ 3 l/h for 5 min. The drop of RBV
during the bolus (DRBV) was measured and UFR was set to 0
again. The rebound of RBV (DRBVþ ) was assessed after further
25 min. For the next 30 min UFR was set depending on the total
amount of fluid to be removed. This schedule of bolus, UF off, low
UF was repeated three times; however, the consecutive boli were not
further analyzed within the scope of this paper. Then the low UFR
was kept until end of treatment. Relative blood volume was
measured with the Fresenius blood volume monitor,48 connected to
a PC for graphical display and storage of data.
Bioimpedance spectroscopy measurements
Bioimpedance measurements were taken immediately before con-
nection of the extracorporeal system with a Hydra 4200 bioimpe-
dance spectrum analyser (Xitron Technologies Inc., San Diego, CA,
USA). The device scans 50 frequencies between 5 kHz and 1 MHz in
B20 s and requires a further 40–70 s for data processing to calculate
ECV and ICV.
Patients were kept recumbent for 5 min before the measurement
to allow for equilibration of fluid shifts in the body. Some patients
with breathing problems in recumbent position had to be kept in
a position between sitting and recumbency. Single-use measure-
ment electrodes were positioned on the wrist and ankle of the side
opposite to the fistula arm. Care was taken to fix electrodes
reproducibly to the same position at different days. Measurement
results were stored with a data acquisition software delivered
by Xitron.
Determining the detection limit of a candidate method
With each of the candidate methods, a physiological property y
is measured as function of the patient’s predialysis weight Wpre.
y may be VCD, CI, DRBV, DRBVþ, ECV, ICV, depending on the
method investigated. A method may be more or less sensitive to
detect changes in fluid status. As Wpre is reduced, y will be affected
by the change in Wpre (desired effect). However, each single y
measurement may also be affected by other physiological effects
not related to weight reduction, and by measurement errors of
the method used (undesired effects). A physiological effect
unrelated to fluid status may, for example be cardiac disease
affecting VCD, a measurement error might be, for example a
device or observer error during VCD measurement. These undesired
effects lead to deviations of the single measurement points from a
smooth regression line that describes the averaged variation of y
with Wpre.
A small change in hydration status, indicated by a small change
in Wpre in this study, can be detected by a candidate method only
reliably if the change Dy caused by the change in Wpre (desired
effect) exceeds the range of variability of y caused by the undesired
effects (this variability may be called the ‘noise level’). The detection
limit of a candidate method for detection of fluid status changes is
therefore defined (in usual terms of sensor technology) as the
minimum change in Wpre between two consecutive measurements
which leads to a change in y just in the range of the ‘noise level.’ It
is obvious that the detection limit of a method decreases (improves)
if the ratio of undesired to desired effects decreases.
For a quantitative analysis of a candidate method, first a linear fit
of y to Wpre is performed for the set of measurements of each
patient:
yðWpreÞ ¼ syWpre þ c ð3Þ
The slope sy indicates the degree of variation of y with Wpre and
thereby the size of the desired effect. sy may vary between patients
due to individual physiological effects. The s.e. ss,y of the slope sy,
which represents the degree of scatter of measurements (y, Wpre)
around the regression line, is also calculated as a measure of
undesired effects. These data are used to demonstrate and discuss
the influence of undesired effects on measurements with all
candidate methods, and also their variability between patients.
The ratio ss,y/sy (termed as fit parameter in the following) was
calculated since it represents a rough quantitative indicator for the
ratio of undesired to desired effects.
The detection limit Wlim of each method was then determined
according to the above definition. Wlim depends on the scatter sy of
measurements around the regression line, but also on the slope sy.
Wlim was therefore calculated as
Wlim ¼ sy

sy ð4Þ
The s.d. sy (which should not be mixed up with the above-
mentioned s.e. of slope ss,y) represents the degree of scatter around
the regression line:
sy ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
i
ðyi  yðWipreÞÞ2
r
ðn  1Þ ð5Þ
In this equation, yi is the measured variable at weight Wpre
i and
y(Wpre
i ) is the regression function value at weight Wpre
i . sy may be
interpreted as the typical single measurement error of the method in
a specific patient. Wlim is the change in weight that corresponds to
this typical error. The smaller the detection limit Wlim, the better is
the performance of the method. As shown in Figure 2, the same s.d.
sy may lead to different Wlim in case of different slopes sy (examples
a, c in Figure 2). A higher slope sy means a stronger variation of y
with Wpre and thereby a reduced Wlim. A smaller sy at the same
slope sy also reduces Wlim (examples b, c).
Wlim is specific for the method used and also be specific for the
patient. Its determination requires a sufficient number of measure-
ments and a sufficient range of variation of Wpre, since the
reliabilities of the linear fit and of sy also depend on these
preconditions. If Wlim is averaged over a sufficient number of
Kidney International (2006) 69, 1609–1620 1619
M Kraemer et al.: Methods to assess fluid status changes o r i g i n a l a r t i c l e
patients, the result may be regarded as the detection limit of the
method itself.
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